Evaluation of the Immune Response Following Treatment with Anti-CTLA-4 Antibody, Radiation Therapy or the Combination in a Murine Model of Breast Cancer

Breast cancers are considered poorly immunogenic tumors. However, several approaches utilizing immunotherapies are being undertaken in the clinic to evaluate their potential for improving outcomes. Radiation therapy (RT) is a highly utilized clinical treatment modality in breast cancer. Radiation is known to modify the tumor microenvironment, induce cytokines and chemokines and has been shown to potentially synergize with immunotherapies. The aim of this work was to evaluate the possible synergy between RT and anti-CTLA-4 therapy in a murine model of breast cancer.